+ |
sirolimus | down-regulates quantity by repression
|
CD86 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-255479 |
|
|
Homo sapiens |
|
pmid |
sentence |
18652845 |
Although RAPA downregulated ILT2, ILT3 and ILT4 expression in DC, the inhibition of T cell proliferation by RAPA-treated DC is predominantly due to the reduction of CD40, CD80 and CD86 expression rather than the propensity to generate FoxP3 expressing regulatory cells. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
sirolimus | down-regulates quantity by repression
|
LILRB1 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-255476 |
|
|
Homo sapiens |
|
pmid |
sentence |
18652845 |
Although RAPA downregulated ILT2, ILT3 and ILT4 expression in DC, the inhibition of T cell proliferation by RAPA-treated DC is predominantly due to the reduction of CD40, CD80 and CD86 expression rather than the propensity to generate FoxP3 expressing regulatory cells. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
sirolimus | down-regulates
chemical inhibition
|
MTOR |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-179483 |
|
|
Homo sapiens |
|
pmid |
sentence |
18636076 |
Rapamycin is an immunosuppressive drug that binds simultaneously to the 12-kda fk506- and rapamycin-binding protein (fkbp12, or fkbp) and the fkbp-rapamycin binding (frb) domain of the mammalian target of rapamycin (mtor) kinase. autophagy is negatively regulated by the mammalian target of rapamycin (mtor) and can be induced in all mammalian cell types by the mtor inhibitor rapamycin. |
|
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-174886 |
|
|
Homo sapiens |
|
pmid |
sentence |
21757781 |
Rapamycin is an immunosuppressive drug that binds simultaneously to the 12-kda fk506- and rapamycin-binding protein (fkbp12, or fkbp) and the fkbp-rapamycin binding (frb) domain of the mammalian ta rget of rapamycin (mtor) kinase. autophagy is negatively regulated by the mammalian target of rapamycin (mtor) and can be induced in all mammalian cell types by the mtor inhibitor rapamycin. |
|
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-153608 |
|
|
Homo sapiens |
|
pmid |
sentence |
17350953 |
Rapamycin is an immunosuppressive drug that binds simultaneously to the 12-kda fk506- and rapamycin-binding protein (fkbp12, or fkbp) and the fkbp-rapamycin binding (frb) domain of the mammalian target of rapamycin (mtor) kinase. autophagy is negatively regulated by the mammalian target of rapamycin (mtor) and can be induced in all mammalian cell types by the mtor inhibitor rapamycin. |
|
Publications: |
3 |
Organism: |
Homo Sapiens |
Pathways: | FLT3-ITD signaling |
+ |
sirolimus | down-regulates quantity by repression
|
CD40 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-255474 |
|
|
Homo sapiens |
|
pmid |
sentence |
18652845 |
Although RAPA downregulated ILT2, ILT3 and ILT4 expression in DC, the inhibition of T cell proliferation by RAPA-treated DC is predominantly due to the reduction of CD40, CD80 and CD86 expression rather than the propensity to generate FoxP3 expressing regulatory cells. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
sirolimus | up-regulates
|
IRS1 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-144159 |
|
|
Homo sapiens |
|
pmid |
sentence |
16452206 |
The mtor inhibitory drug rapamycin up-regulates irs-1 protein levels and induces akt phosphorylation, protein kinase activity, and downstream signaling. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
sirolimus | down-regulates
chemical inhibition
|
mTORC1 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-219385 |
|
|
in vitro |
|
pmid |
sentence |
17350953 |
Rapamycin is an immunosuppressive drug that binds simultaneously to the 12-kDa FK506- and rapamycin-binding protein (FKBP12, or FKBP) and the FKBP-rapamycin binding (FRB) domain of the mammalian target of rapamycin (mTOR) kinase. The resulting ternary complex has been used to conditionally perturb protein function, and one such method involves perturbation of a protein of interest through its mislocalization. |
|
Publications: |
1 |
Organism: |
In Vitro |
+ |
sirolimus | down-regulates quantity by repression
|
CD80 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-255475 |
|
|
Homo sapiens |
|
pmid |
sentence |
18652845 |
Although RAPA downregulated ILT2, ILT3 and ILT4 expression in DC, the inhibition of T cell proliferation by RAPA-treated DC is predominantly due to the reduction of CD40, CD80 and CD86 expression rather than the propensity to generate FoxP3 expressing regulatory cells. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
sirolimus | up-regulates
|
AKT1 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-252643 |
|
|
Homo sapiens |
|
pmid |
sentence |
16452206 |
We now show that mtor inhibition induces insulin receptor substrate-1 expression and abrogates feedback the pathway, resulting in akt activation both in cancer cell lines and in patient tumors treated with the rapamycin derivative, rad001. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
Pathways: | FLT3-ITD signaling |
+ |
sirolimus | down-regulates quantity by repression
|
LILRB2 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-255477 |
|
|
Homo sapiens |
|
pmid |
sentence |
18652845 |
Although RAPA downregulated ILT2, ILT3 and ILT4 expression in DC, the inhibition of T cell proliferation by RAPA-treated DC is predominantly due to the reduction of CD40, CD80 and CD86 expression rather than the propensity to generate FoxP3 expressing regulatory cells. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
sirolimus | down-regulates activity
chemical inhibition
|
MTOR |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-261074 |
|
|
Homo sapiens |
|
pmid |
sentence |
7566123 |
Consistent with an essential role for FRAP kinase activity in vivo, autophosphorylation of FRAP is inhibited by FKBP12-rapamycin. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
Pathways: | FLT3-ITD signaling |
+ |
sirolimus | down-regulates quantity by repression
|
LILRB4 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-255478 |
|
|
Homo sapiens |
|
pmid |
sentence |
18652845 |
Although RAPA downregulated ILT2, ILT3 and ILT4 expression in DC, the inhibition of T cell proliferation by RAPA-treated DC is predominantly due to the reduction of CD40, CD80 and CD86 expression rather than the propensity to generate FoxP3 expressing regulatory cells. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
sirolimus | up-regulates
|
AKT |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-144156 |
|
|
Homo sapiens |
|
pmid |
sentence |
16452206 |
We now show that mtor inhibition induces insulin receptor substrate-1 expression and abrogates feedback the pathway, resulting in akt activation both in cancer cell lines and in patient tumors treated with the rapamycin derivative, rad001. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
Pathways: | FLT3-ITD signaling |